Industries de la santé
New data confirm high efficacy of Gilenya® in achieving ‘no evidence of disease activity (NEDA)’ based on four key measures of MS



16 Septembre 2014
A key treatment goal for patients with MS is ‘no evidence of disease activity’ (NEDA), currently defined as no relapses, MRI lesions and disability progression |Including MS-related brain shrinkage (brain volume loss) as a fourth key measure captures underlying damage that begins early in MS and is associated with loss of function
The likelihood of achieving NEDA across four key...